SML3650
CTPI-2
≥98% (HPLC)
别名:
2-(4-Chloro-3-nitrobenzenesulfonamido)benzoic acid, 2-[[(4-Chloro-3-nitrophenyl)sulfonyl]amino]benzoic acid, CTPI 2, CTPI2
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C13H9ClN2O6S
化学文摘社编号:
分子量:
356.74
UNSPSC Code:
12352200
NACRES:
NA.25
MDL number:
产品名称
CTPI-2, ≥98% (HPLC)
SMILES string
[S](=O)(=O)(Nc2c(cccc2)C(=O)O)c1cc(c(cc1)Cl)[N+](=O)[O-]
InChI
1S/C13H9ClN2O6S/c14-10-6-5-8(7-12(10)16(19)20)23(21,22)15-11-4-2-1-3-9(11)13(17)18/h1-7,15H,(H,17,18)
InChI key
NJTHPOSQGFJTDP-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
CTPI-2 is a selective mitochondrial citrate transporter (SLC25A1) inhibitor that displays H1299 anti-proliferation activity in a SLC25A1-dependent manner (IC50 <10 μM). When compared with CTPI-1, CTPI-2 exhibits 20-fold higher target affinity (hSLC25A1 KD = 3.5 μM vs. 63.6 μM, respectively) and is ~1000-fold more potent against H1299 sphere-forming capacity. CTPI-2 inhibits mitochondrial respiration and formation of patient NSCLC tumors-derived CSCs spheres in cultures (10-50 μM), as well as suppresses the growth of patent-derived NSCLC exnografts in mice in vivo (28 mg/kg q.o.d. i.p.).
Selective mitochondrial citrate transporter (SLC25A1) inhibitor with anti-cancer efficacy in cultures and in vivo.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Terumasa Umemoto et al.
The EMBO journal, 41(8), e109463-e109463 (2022-03-02)
In order to support bone marrow regeneration after myeloablation, hematopoietic stem cells (HSCs) actively divide to provide both stem and progenitor cells. However, the mechanisms regulating HSC function and cell fate choice during hematopoietic recovery remain unclear. We herein provide
Harvey R Fernandez et al.
Cell death and differentiation, 25(7), 1239-1258 (2018-04-14)
Therapy resistance represents a clinical challenge for advanced non-small cell lung cancer (NSCLC), which still remains an incurable disease. There is growing evidence that cancer-initiating or cancer stem cells (CSCs) provide a reservoir of slow-growing dormant populations of cells with
Kexu Xiang et al.
Cell death & disease, 13(7), 641-641 (2022-07-23)
Oncogenic mutations in metabolic genes and associated oncometabolite accumulation support cancer progression but can also restrict cellular functions needed to cope with DNA damage. For example, gain-of-function mutations in isocitrate dehydrogenase (IDH) and the resulting accumulation of the oncometabolite D-2-hydroxyglutarate
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持